[1] Kaushansky K. The molecular mechanisms that control thrombopoiesis[J].J Clin Invest,2005,115(12):3339-3347.DOI:10.1172/JCI26674.
[2] Stuart MJ, Murphy S, Oski FA. A simple nonradioisotope technic for the determination of platelet life-span[J].N Engl J Med,1975,292(25):1310-1313.DOI:10.1056/NEJM197506192922502.
[3] 中国成人血小板减少症急诊管理共识专家组. 中国成人血小板减少症急诊管理专家共识[J]. 中华急诊医学杂志,2022,31(2):161-168.DOI:10.3760/cma.j.issn.1671-0282. 2022.02.005.
[4] Pogorzelska K, Krętowska A, Krawczuk-Rybak M, et al. Characteristics of platelet indices and their prognostic significance in selected medical condition - a systematic review[J].Adv Med Sci,2020,65(2):310-315.DOI:10.1016/j.advms.2020.05.002.
[5] 李欣明.脑梗死患者免疫状态和血小板参数及活化指标的变化分析[J].国际医药卫生导报,2017,23(15):2394-2396.DOI:10.3760/cma.j.issn.1007-1245.2017.15.022.
[6] 谭秀芳,孙红娟.骨髓细胞及血小板参数联合诊断血液疾病的价值研究[J].国际检验医学杂志,2018,39(3):336-338.DOI:10.3969/j.issn.1673-4130.2018.03.023.
[7] Schifferli A, Heiri A, Imbach P, et al. Misdiagnosed thrombocytopenia in children and adolescents: analysis of the pediatric and adult registry on chronic ITP[J].Blood Adv,2021,5(6):1617-1626.DOI:10.1182/bloodadvances. 2020003004.
[8] Cooper N. A review of the management of childhood immune thrombocytopenia: how can we provide an evidence-based approach?[J].Br J Haematol,2014,165(6):756-767.DOI:10.1111/bjh.12889.
[9] 谢军,刘彦慧.特发性血小板减少性紫癜患者巨核细胞和血小板参数的探讨[J].中国实验血液学杂志,2015,23(5):1397-1399.DOI:10.7534/j.issn.1009-2137.2015.05.033.
[10] 中国儿童原发性免疫性血小板减少症诊断与治疗指南改编工作组,中华医学会儿科学分会血液学组,中华儿科杂志编辑委员会.中国儿童原发性免疫性血小板减少症诊断与治疗改编指南(2021版)[J].中华儿科杂志,2021,59(10):810-819.DOI:10.3760/cma.j.cn112140-20210509-00397.
[11] 付蓉.再生障碍性贫血诊断与治疗中国专家共识(2017年版)[J].中华血液学杂志,2017,38(1):1-5.DOI:10.3760/cma.j.issn.0253-2727.2017.01.001.
[12] 中华医学会血液学分会干细胞应用学组,中华医学会儿科学分会.异基因造血干细胞移植治疗儿童急性淋巴细胞白血病中国专家共识(2022年版)[J].中华血液学杂志,2022,43(10):793-801.DOI:10.3760/cma.j.issn.0253-2727. 2022.10.001.
[13] 中华医学会血液学分会干细胞应用学组,中华医学会儿科学分会.异基因造血干细胞移植治疗儿童急性髓系白血病(非急性早幼粒细胞白血病)中国专家共识(2022年版)[J].中华血液学杂志,2022,43(10):802-809.DOI:10.3760/cma.j.issn.0253-2727.2022.10.002.
[14] 梅恒,胡豫.成人原发免疫性血小板减少症诊断与治疗中国指南(2020年版)解读[J].临床内科杂志,2021,38(6):431-432.DOI:10.3969/j.issn.1001-9057.2021.06.023.
[15] Vinholt PJ, Hvas AM, Nybo M. An overview of platelet indices and methods for evaluating platelet function in thrombocytopenic patients[J].Eur J Haematol,2014,92(5):367-376.DOI:10.1111/ejh.12262.
[16] Grace RF, Lambert MP. An update on pediatric ITP: differentiating primary ITP, IPD, and PID[J].Blood,2022,140(6):542-555.DOI:10.1182/blood.2020006480.
[17] Lucijanic M, Mitrovic Z, Cicic D, et al. Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis[J].Int J Hematol,2018,107(2):166-172.DOI:10.1007/s12185-017-2348-4.
[18] Espinosa-Campos RA, De la O-Hernández SG, González-Zárate MG, et al. Controlled clinical study to evaluate the utility of the platelet distribution width (PDW) in the diagnosis of acute appendicitis[J].Cir Cir,2020,88(5):630-634.DOI:10.24875/CIRU.20000967.
[19] Grotto HZ, Noronha JF. Platelet larger cell ratio (P-LCR) in patients with dyslipidemia[J].Clin Lab Haematol,2004,26(5):347-349.DOI:10.1111/j.1365-2257.2004.00634.x.
[20] Wang JY, Ye S, Zhong H. The role of bone marrow microenvironment in platelet production and their implications for the treatment of thrombocytopenic diseases[J].Hematology,2017,22(10):630-639.DOI:10.1080/10245332.2017.1333274.
[21] 黄舜明.全自动血液分析仪血小板参数检测对血小板减少性疾病的早期诊断价值[J].白求恩医学杂志,2017,15(1):111-112.DOI:10.16485/j.issn.2095-7858.2017.01.057.
[22] 白静,刘文君.儿童原发性免疫性血小板减少症血小板参数及功能变化[J].临床儿科杂志,2015,33(9):797-801.DOI:10.3969/j.issn.1000-3606.2015.09.009.
[23] 郝英婵,程莉,曾菊,等.MPV、PDW、P-LCC等参数联合检测在儿童免疫性血小板减少性紫癜中的诊断价值[J].国际检验医学杂志,2022,43(8):1002-1005.DOI:10.3969/j.issn.1673-4130.2022.08.022.
[24] 刘冬梅,王莉莉,董明华,等.血小板抗体和血清白细胞介素在特发性血小板减少性紫癜患者诊断及预后分析研究[J].国际医药卫生导报,2019,25(3):430-434.DOI:10.3760/cma.j.issn.1007-1245.2019.03.030.
[25] Cines DB, Bussel JB, Liebman HA, et al. The ITP syndrome: pathogenic and clinical diversity[J].Blood,2009,113(26):6511-6521.DOI:10.1182/blood-2009-01-129155.
[26] Kim TO, Despotovic JM. Primary and secondary immune cytopenias: evaluation and treatment approach in children[J].Hematol Oncol Clin North Am,2019,33(3):489-506.DOI:10.1016/j.hoc.2019.01.005.
[27] Grimaldi-Bensouda L, Nordon C, Leblanc T, et al. Childhood immune thrombocytopenia: a nationwide cohort study on condition management and outcomes[J].Pediatr Blood Cancer,2017,64(7):27905681.DOI:10.1002/pbc.26389.
[28] Ikuse T, Toda M, Kashiwagi K, et al. Efficacy of helicobacterpylori eradication therapy on platelet recovery in pediatric immune thrombocytopenic purpura-case series and a systematic review[J].Microorganisms,2020,8(10):1457.DOI:10.3390/microorganisms8101457.
[29] Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the international working group[J].Blood,2013,121(14):2596-2606.DOI:10.1182/blood-2012-07-442392.
[30] Vinholt PJ. The role of platelets in bleeding in patients with thrombocytopenia and hematological disease[J].Clin Chem Lab Med,2019,57(12):1808-1817.DOI:10.1515/cclm-2019-0380.
[31] 童汝雁,金皎,黄璟,等.儿童免疫性血小板减少症预后相关因素[J].中华实用儿科临床杂志,2019,34(11):837-841.DOI:10.3760/cma.j.issn.2095-428X.2019.11.009.
|